Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Eloxx Pharmaceuticals

Request full access

Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases, including cystic fibrosis, Duchenne muscular dystrophy…

Watertown, United StatesFounded 2013Biotech & Life Sciences

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel RNA-modulating therapies for rare and ultra-rare genetic diseases. The company's primary target is diseases caused by nonsense mutations, which are genetic alterations that prematurely stop protein synthesis. Eloxx's lead investigational drug, ELX-02, is designed to restore the production of functional proteins by enabling the ribosome to read through these premature stop codons, a process known as translation. Currently, ELX-02 is in Phase 2 clinical trials for cystic fibrosis patients with diagnosed nonsense mutations.

Eloxx operates in the biopharmaceutical market, primarily targeting patients with high unmet medical needs. The company employs a research and development strategy that focuses on identifying patient populations with nonsense mutations, establishing preclinical models, and navigating the regulatory pathways for Orphan Drug development. Eloxx's business model revolves around the development and commercialization of its proprietary small molecule compounds, which are designed to be disease-modifying therapies.

Revenue generation for Eloxx is anticipated through the successful development, regulatory approval, and commercialization of its drug candidates. The company also places a strong emphasis on patient advocacy, ensuring that patient needs are central to its drug development process.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2013
Headquarters
Watertown, United States
Listing
IPO 2016
Employees
12
Open positions
None listed
Dealroom signal
71.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Orthopedic, Biotech and Pharma, Woman Founder, proteomics, DT and LS, science-based
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Jun 2026 $66M — Undisclosed ↗
POST IPO DEBTDebt Jul 2024 $3.2M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 $0 — −$6.3M —
2025 $0 -100% −$6.3M —
2024 $6.4M — −$2.2M -35%
2023 $0 — −$16M —
2022 $0 — −$34M —
2021 — — −$66M —
2020 — — −$25M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Eloxx Pharmaceuticals website traffic

Latest recorded traffic for Eloxx Pharmaceuticals is 3.2K monthly website visits, up 88.2% over the last three months. Eloxx Pharmaceuticals's team declined 45.5% over the past year.

Latest monthly visits3.2K 3-month web change+88.2% 1-year team growth-45.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Eloxx Pharmaceuticals in the Watertown ecosystem

Live from Dealroom

The Eloxx Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Cystic Fibrosis Foundation

Series B and later10 investors entered at this stage

  • Pontifax Funds
  • DSC Investment
  • Catalyst CEL Fund
  • EQT Life Sciences
  • Dr. Phil Frost
  • OPKO Health
  • GF Securities
  • Quark Venture
  • Korea Investment Partners
  • Hercules Capital

Other known investors5 additional known investors

  • Sevion Therapeutics
  • Technion Israel Institute of Technology
  • Advent Life Sciences
  • China Everbright Limited
  • Medison Ventures
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States60%
🇮🇱 Israel30%
🇮🇪 Ireland10%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Eloxx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Eloxx Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.